SURI
Simplify Propel Opportunities ETF
Price Chart
Latest Quote
$17.02
| Previous Close | $17.36 |
| Open | $17.30 |
| Day High | $17.02 |
| Day Low | $17.00 |
| Volume | 1,803 |
Fund Information
| Quarterly Dividend / Yield | N/A / 15.48% |
| Net Assets | $75.37M |
| Expense Ratio | 2.56% |
| Category | Health |
| Fund Family | Simplify Asset Management |
| Net Asset Value | $17.27 |
| Premium/Discount | -1.44% |
| Quarterly Dividend Yield | 15.48% |
| P/E Ratio | 22.17 |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $17.37 |
| SMA50 | $17.30 |
| SMA200 | $16.05 |
| RSI | 38.80 |
| ATR | 0.2924 |
| Rel Volume | 1.09 |
Performance History
| Week | -3.25% |
| Month | -1.58% |
| Quarter | +4.20% |
| 6 Months | +8.24% |
| YTD | +5.72% |
| Year | +24.51% |
| 3 Years | +14.43% |
| 10 Years | +15.44% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $17.02 | 2,400 |
| 2026-06-17 | $17.36 | 400 |
| 2026-06-16 | $17.30 | 2,100 |
| 2026-06-15 | $17.37 | 2,800 |
| 2026-06-12 | $17.53 | 700 |
| 2026-06-11 | $17.59 | 1,700 |
| 2026-06-10 | $17.40 | 1,100 |
| 2026-06-09 | $17.20 | 1,600 |
| 2026-06-08 | $17.00 | 1,700 |
| 2026-06-05 | $16.85 | 5,600 |
| 2026-06-04 | $17.33 | 2,500 |
| 2026-06-03 | $16.95 | 3,400 |
| 2026-06-02 | $17.15 | 4,100 |
| 2026-06-01 | $17.40 | 3,000 |
| 2026-05-29 | $17.70 | 4,200 |
| 2026-05-28 | $17.76 | 1,600 |
| 2026-05-27 | $17.54 | 1,200 |
| 2026-05-26 | $17.57 | 600 |
| 2026-05-22 | $17.70 | 800 |
| 2026-05-21 | $17.61 | 2,700 |
| 2026-05-20 | $17.40 | 1,700 |
| 2026-05-19 | $17.29 | 1,300 |
About Simplify Propel Opportunities ETF
The fund is an actively managed exchange-traded fund. The Sub-Adviser concentrates the fund's investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The fund is non-diversified.
